[go: up one dir, main page]

IN2013MU01177A - - Google Patents

Info

Publication number
IN2013MU01177A
IN2013MU01177A IN1177MU2013A IN2013MU01177A IN 2013MU01177 A IN2013MU01177 A IN 2013MU01177A IN 1177MU2013 A IN1177MU2013 A IN 1177MU2013A IN 2013MU01177 A IN2013MU01177 A IN 2013MU01177A
Authority
IN
India
Prior art keywords
present
tadalafil
stable pharmaceutical
excipienls
particle
Prior art date
Application number
Inventor
Pavan Kumar M
Jamloki Ashutosh
Bhattacharya Sautik
Sehgel Ashish
Original Assignee
Astron Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astron Res Ltd filed Critical Astron Res Ltd
Priority to IN1177MU2013 priority Critical patent/IN2013MU01177A/en
Priority to PCT/IN2014/000196 priority patent/WO2014167579A2/en
Publication of IN2013MU01177A publication Critical patent/IN2013MU01177A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to stable pharmaceutical compositions of Tadalafil for oral administration comprising tadalafil particles having D90 particle si/.e greater than about 40 μm and one or more pharmaceutically acceptable excipienls, Further the present invention also discloses the process for the preparation of the said stable pharmaceutical composition.
IN1177MU2013 2013-03-28 2014-03-28 IN2013MU01177A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN1177MU2013 IN2013MU01177A (en) 2013-03-28 2014-03-28
PCT/IN2014/000196 WO2014167579A2 (en) 2013-03-28 2014-03-28 Stable pharmaceutical compositions of tadalafil

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1177MU2013 IN2013MU01177A (en) 2013-03-28 2014-03-28

Publications (1)

Publication Number Publication Date
IN2013MU01177A true IN2013MU01177A (en) 2015-04-17

Family

ID=51690088

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1177MU2013 IN2013MU01177A (en) 2013-03-28 2014-03-28

Country Status (2)

Country Link
IN (1) IN2013MU01177A (en)
WO (1) WO2014167579A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX379254B (en) * 2016-02-26 2025-03-10 Apotex Inc Novel pharmaceutical formulations comprising a pds5 inhibitor
CN113855639B (en) * 2021-11-04 2023-03-24 昆明源瑞制药有限公司 Tadalafil tablet and preparation method thereof
CN115089551B (en) * 2022-04-07 2024-03-29 江西药都仁和制药有限公司 Tadalafil tablet and preparation method thereof
WO2023232215A1 (en) * 2022-06-02 2023-12-07 Rontis Hellas S.A. Improved pharmaceutical composition containing tadalafil and process for the preparation thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012095151A1 (en) * 2010-12-23 2012-07-19 Zaklady Farmaceutyczne Polpharma Sa Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
EP2654723B1 (en) * 2010-12-23 2014-12-31 Zaklady Farmaceutyczne Polpharma SA Solid pharmaceutical dosage forms comprising tadalafil and methods of preparation thereof
WO2014092661A1 (en) * 2012-01-18 2014-06-19 Mahmut Bilgic Particulate formulations of tadalafil in effervescent form

Also Published As

Publication number Publication date
WO2014167579A2 (en) 2014-10-16
WO2014167579A3 (en) 2014-12-24

Similar Documents

Publication Publication Date Title
SG10201810985XA (en) Tofacitinib oral sustained release dosage forms
MX2021011906A (en) Delayed release compositions of linaclotide.
MX2013001677A (en) Stable formulations of linaclotide.
SV2016005236A (en) COMPOSITE FORMULATION FOR ORAL ADMINISTRATION INCLUDING EZETIMIBE AND ROSUVASTATIN
MX2015012414A (en) Salt of omecamtiv mecarbil and process for preparing salt.
IN2013MU03583A (en)
MX2012001660A (en) Linaclotide-containing formulations for oral administration.
WO2014137797A3 (en) Stable glucokinase activator compositions
MX364946B (en) Improved adjuvant system for oral vaccine adminstration.
PH12013500784A1 (en) Pharmaceutical compositions comprising nano size droplets of skin whitening agents
WO2013057741A3 (en) Pharmaceutical compositions of ursodeoxycholic acid
WO2014068586A3 (en) Solid oral compositions of tolvaptan
WO2015092810A3 (en) Amorphous form of idelalisib
MX2016001422A (en) Pharmaceutical compositions of fingolimod.
IN2013MU01177A (en)
MX366829B (en) Itraconazole compositions and dosage forms, and methods of using the same.
MX2015010486A (en) Chewable composition for oral administration and process for preparing thereof.
NZ712341A (en) A crystalline form of an anxiolytic compound
EA032913B1 (en) Formulations of pyrimidinedione derivative compounds
GEP201706672B (en) Dry powder inhaler compositions comprising long acting muscorinic antagonists
MX2018011016A (en) Stable formulations for lyophilizing therapeutic particles.
WO2016197042A8 (en) Modified or targeted release formulations of linaclotide
WO2014122671A3 (en) Solid oral compositions of saxagliptin
MX2019015869A (en) New oral formulations of belinostat.
IN2013CH04314A (en)